U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
CAMBRIDGE, Mass., Oct. 27, 2016 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, November 3, 2016 at 9:00 a.m. ET to discuss financial results for the third quarter of 2016. Genocea management will provide an update on the Company's recent progress and upcoming milestones.
Interested participants and investors may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referencing the conference ID number 96207224. To join the live webcast please visit the investor relations section of the Genocea website at http://ir.genocea.com.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 30 days.
About Genocea Biosciences Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus (development suspended pending further data analysis and consultation with our advisers), and earlier-stage programs in cancer immunotherapy, chlamydia, genital herpes prophylaxis and malaria. For more information, please visit the company's website at www.genocea.com.
For media: Liz Bryan Spectrum Science Communications, Inc. O: 202-955-6222 [email protected] For investors: Jonathan Poole Genocea Biosciences, Inc. O: 617-876-8191 [email protected]
